Ratings Cue Health Inc.

Equities

HLTH

US2297901009

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-29 pm EDT			5-day change	1st Jan Change
0.146 ^USD	+3.55%		+3.55%	-10.15%

Apr. 24	Cue Health Inc. Announces Chief Financial Officer Changes, Effective as of May 13, 2024	CI
Apr. 09	Cue Health Inc. Receives Response Letter from the U.S. Food and Drug Administration Regarding Its De Novo Request	CI

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Overall, and from a short-term perspective, the company presents an interesting fundamental situation.

Strengths

Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
The company is one of the most undervalued, with an "enterprise value to sales" ratio at 0.02 for the 2024 fiscal year.
The company appears to be poorly valued given its net asset value.
For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.

Weaknesses

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
Low profitability weakens the company.
One of the major weak points of the company is its financial situation.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
For the last few months, analysts have been revising downwards their earnings forecast.
Over the past four months, analysts' average price target has been revised downwards significantly.
The overall consensus opinion of analysts has deteriorated sharply over the past four months.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Software

	1st Jan change	Capi.	ESG Refinitiv
CUE HEALTH INC.	-10.15%	23.23M	C
MICROSOFT CORPORATION	+6.97%	2,990B	C+
SYNOPSYS INC.	+5.80%	83.1B	B
CADENCE DESIGN SYSTEMS, INC.	+3.72%	76.88B	B+
DASSAULT SYSTÈMES SE	-15.18%	52.88B	B+
PALANTIR TECHNOLOGIES INC.	+32.96%	50.84B	D+
ATLASSIAN CORPORATION	-25.56%	46.09B	B-
THE TRADE DESK, INC.	+17.43%	41.3B	D+
SEA LIMITED	+59.31%	37.06B	D+
TAKE-TWO INTERACTIVE SOFTWARE, INC.	-10.36%	24.61B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes